Stocks Health care KLRS
NASDAQ · Health careKalaris Therapeutics, Inc. (KLRS)
It posted a net loss of $44.3M. In fiscal 2025 capital spending exceeded operating cash flow by $38.6M. At June 30, 2026 it held $43.2M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Kalaris Therapeutics, Inc. does
Kalaris Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker KLRS.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$43.4M | -$2.85 | -$38.6M |
| 2024 | n/a | -$69.2M | -$51.77 | n/a |
| 2023 | n/a | -$190.4M | -$185.76 | n/a |
| 2022 | n/a | -$168.7M | -$223.32 | n/a |
| 2021 | n/a | -$172M | -$278.14 | -$106.3M |
| 2020 | n/a | -$69.8M | -$262.91 | -$61M |
Latest SEC filings
What Kalaris Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- July 20, 2026
- July 17, 2026
- July 6, 2026
- June 4, 2026
- May 22, 2026Activist stake changed SCHEDULE 13D/A
- May 12, 2026Quarterly report 10-Q · period to March 31, 2026
- May 12, 2026
- April 24, 2026
Questions about KLRS
What does Kalaris Therapeutics, Inc. do?
Kalaris Therapeutics, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker KLRS.
Is Kalaris Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $44.3M.
When did Kalaris Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 28, 2026.
Similar companies
Follow KLRS
Get an email when Kalaris Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow KLRS: get an email when it filesWhere the numbers come from
Financial figures are the values Kalaris Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.